Wasatch Advisors’s Cogent Biosciences COGT Stock Holding History

Wasatch Advisors’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-63,612	Closed	-$366K	–	248
2019 Q3	$366K	Hold	63,612	–	–	﹤0.01%	238
2019 Q2	$667K	Hold	63,612	–	–	0.01%	232
2019 Q1	$1.12M	Buy	63,612 +24,953	+65%	+$427K	0.01%	221
2018 Q4	$680K	Sell	38,659 -27,125	-41%	-$803K	0.01%	224
2018 Q3	$2.71M	Sell	65,784 -1,122	-2%	-$63.2K	0.03%	211
2018 Q2	$3.84M	Buy	66,906 +3,381	+5%	+$163K	0.05%	179
2018 Q1	$2.82M	Buy	+63,525	New	+$2.82M	0.04%	197

Other funds holding COGT

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Wasatch Advisors's COGT Position: Q4 2019 in Review

Wasatch Advisors sold out of Cogent Biosciences (COGT) in Q4 2019, closing a stake of 63,612 shares — an estimated $366K sold.

Wasatch Advisors first reported a position in COGT in Q1 2018 and held it in 7 quarters. The position peaked at $3.84M in Q2 2018. 27 funds tracked by Wall St. Rank hold COGT as of Q4 2019.

Wasatch Advisors reported no remaining Cogent Biosciences position as of Q4 2019 after selling out during the quarter.
Wasatch Advisors sold 63,612 Cogent Biosciences shares in Q4 2019, an estimated $366K.
Wasatch Advisors first reported a position in Cogent Biosciences in Q1 2018 and held it in 7 quarters.
Wasatch Advisors's Cogent Biosciences position peaked at $3.84M in Q2 2018.
27 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2019.

Based on Wasatch Advisors's 13F filing for Q4 2019, filed 13 Feb 2020.